Stock DNA
Pharmaceuticals & Biotechnology
USD 208 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-4.76
-999,999.00%
-70.96
Revenue and Profits:
Net Sales:
11 Million
(Quarterly Results - Sep 2025)
Net Profit:
10 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-30.44%
0%
-30.44%
6 Months
-39.11%
0%
-39.11%
1 Year
-12.48%
0%
-12.48%
2 Years
137.79%
0%
137.79%
3 Years
110.04%
0%
110.04%
4 Years
-57.99%
0%
-57.99%
5 Years
-62.96%
0%
-62.96%
SANUWAVE Health, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
74.79%
EBIT Growth (5y)
20.23%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
42.75%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-18.15
EV to EBIT
39.06
EV to EBITDA
33.43
EV to Capital Employed
77.47
EV to Sales
7.31
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
198.32%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 12 Schemes (10.65%)
Foreign Institutions
Held by 9 Foreign Institutions (0.72%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
11.50
10.20
12.75%
Operating Profit (PBDIT) excl Other Income
1.80
2.20
-18.18%
Interest
1.70
1.90
-10.53%
Exceptional Items
5.40
1.00
440.00%
Consolidate Net Profit
10.30
1.10
836.36%
Operating Profit Margin (Excl OI)
128.10%
184.70%
-5.66%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 12.75% vs 9.68% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 836.36% vs 119.30% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
32.60
20.40
59.80%
Operating Profit (PBDIT) excl Other Income
6.60
0.50
1,220.00%
Interest
13.60
15.60
-12.82%
Exceptional Items
-25.10
-9.60
-161.46%
Consolidate Net Profit
-31.40
-25.80
-21.71%
Operating Profit Margin (Excl OI)
166.00%
-26.50%
19.25%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 59.80% vs 22.16% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -21.71% vs -150.49% in Dec 2023






